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Midazolam is widely used as a sedative agent to produce amnesia in patients undergoing fibre-optic bronchoscopy.
However, if a patient does not receive suYcient local anaesthesia, continuous severe cough and physical movement
may interrupt the procedure and reduce its safety. We therefore examined whether codeine phosphate is a useful
premedication for bronchoscopy. The study design was a randomized comparison between codeine phosphate and
a placebo in patients undergoing light local anaesthesia and midazolam sedation. We used low dose local anaesthesia
(5 ml of nebulized 2% xylocaine) on the assumption of insuYcient local anaesthesia. Patients were allocated to
receive codeine phosphate 0·4 mg kg"1 or a saline placebo 60 min before they were sedated with i.v. midazolam. If
the patients exhibited severe cough during bronchoscopy, intrabronchial supplemental local anaesthesia (2%
xylocaine solution in 1 ml increments) was instilled via a bronchoscope to the trachea and segmental bronchi to
suppress the cough. The dose of supplemental xylocaine was assessed and the requirements were significantly lower
in the codeine group compared to the placebo group: 36·4&10·2 mg vs. 95·1&24·6 mg, respectively. After
bronchoscopy, patients were interviewed by a doctor to assess their willingness to undergo a repeat procedure if one
was clinically indicated, but no significant diVerence was observed between the two groups. If local anaesthesia is
insuYcient, midazolam together with codeine phosphate premedication is useful for both the patient and the
bronchoscopist.
RESPIR. MED. (1999) 93, 413–415Introduction
Midazolam is widely used as a sedative agent in patients
undergoing fibre-optic bronchoscopy (1). However, the
eVect of midazolam as an anti-tussive agent is limited.
Severe cough and body movements occur during bron-
choscopy, especially in patients that cannot inspire enough
and reject the inspiration of xylocaine spray as a localized
anaesthetic. Codeine phosphate is frequently used as an
anti-tussive agent, and we examined the usefulness of
this drug as a premedication for bronchoscopy. The aim
of this study was to assess the anti-tussive eVect of
codeine phosphate under midazolam sedation during
bronchoscopy.Received 2 December 1998 and accepted in revised form 2
March 1999.
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Of 165 patients undergoing routine diagnostic fibre-optic
bronchoscopy without transbronchial biopsy and brushing,
89 consented to enter a consecutive double-blind study to
compare codeine phosphate premedication with a saline
placebo. Indications of bronchoscopy included productive
cough, haemoptysis or bronchogenic neoplasm. Bron-
choscopy was performed in Ishikawa Prefectural Central
Hospital and Nakamura Hospital. A flexible fibre-optic
bronchoscope (Olympus BF-1T30, 1T200; OD, 6 mm) was
introduced orally using a mouthpiece. All patients received
0·5 mg of i.v. atropine 30 min before bronchoscopy. The
patients in the codeine group received codeine phosphate,
0·4 mg kg"1 60 min before bronchoscopy, while the
patients in the placebo group received a saline solution.
After 5 ml of nebulized 2% xylocaine as a light local
anaesthetic had been administered to the oropharynx, all
patients received midazolam, 0·15 mg kg"1 i.v. over 30 s.
Arterial blood gas analysis was performed in all patients
before bronchoscopy. Patients with PaO2 <70 Torr,
PaCO2 >60 or SaO2 <85% in room air (Fio2=21%) were
excluded as midazolam sedation was not indicated.? 1999 W. B. SAUNDERS COMPANY LTD
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electrocardiographical (ECG) recording, pulse oximetry
and automatic blood pressure recording. At midazolam
administration, if patients exhibited an oxygen saturation
of <92%, 0·4 mg i.v. fulmazenil was immediately adminis-
tered. Supplemental oxygen (2 l min"1) was routinely given
via a nasal cannula to all patients. If patients exhibited
severe cough, intrabronchial supplemental local anaesthesia
(2% xylocaine solution in 1 ml increments) was instilled via
the bronchoscope to the trachea and segmental bronchi
to suppress the cough. The dose of supplemental local
anaesthesia required was noted for each patient. After
bronchoscopy, patients were administered i.v. fulmazenil,
0.4 mg and assessed by a doctor regarding how comfortable
they had been during bronchoscopy and their willingness
to undergo a repeat procedure if one was clinically
indicated.
Statistical analysis was performed using the Mann–
Whitney U-test and chi-squared test.Table 1. Patient characteristics. Sex, age, body weight and blood gas analysis of patients in a
placebo-controlled comparison of codeine phosphate premedication during fibre-optic bron-
choscopy
Codeine
(n=44)
Placebo
(n=45) P-value
Men/women 23/21 20/25
Mean age (years) 64·3&11·6 66·7&9·7 n.s.*
Mean weight (kg) 48·5&17·6 50·8&17·9 n.s.
PaCO2 (Torr) 42·3&4·6 42·9&3·8 n.s.
PaO2 (Torr) 81·3&10·3 82·8&8·7 n.s.
O2 sat (%) 94·9&2·1 95·58&1·2 n.s.
Statistical analysis was carried out using the Mann–Whitney U-test. (Mean values&sd).
*n.s., not significant.Table 2. Oxygen saturation profile, supplemental local anaesthesia and the number of patients
willing to undergo repeat examinations
Codeine
(n=45)
Placebo
(n=44) P-value
SaO2 <90% (n) 4/45 14/44 <0·05
SaO2 <85% (n) 0/45 1/44 n.s.*
Mean lowest oxygen 93·8&4·8 91·5&2·4 <0·05
Xylocaine additional (mg) 36·4&10·2 95·1&24·6 <0·01
Willingness to repeat (n/total) 32/45 28/44 n.s.
Statistical analysis was carried out using the Mann–Whitney U-test and chi-squared test.
*n.s., not significant.Results
A total of 89 patients were studied, 45 of whom received
codeine phosphate and 44 of whom received a salinesolution as a placebo. There were no significant diVerences
between the codeine group and the placebo group in terms
of age, PaO2, PaCO2 or oxygen saturation in room air
(Table 1). Bronchoscopic procedures were performed to
observe the respiratory tract in most patients, but broncho-
alveolar lavage was performed in nine patients in both
groups. The mean injection dose of midazolam was
5·0&2·5 m and the induction time was 90–160 s. Three
patients showed verbomania and one patient hiccups.
Blood pressure and heart rate remained stable. Oxygen
desaturation was noted in both groups. There was a signifi-
cant diVerence in the number of patients whose oxygen
saturation was <90% on at least one occasion during the
procedure, but only one patient showed saturation <85%.
Concerning the mean lowest oxygen, the codeine group
showed a significantly higher value. All patients were
amnesiac regarding the procedure. The hiccups disappeared
during the procedure. The dose of supplemental
local anaesthetic requirements was significantly lower in
the codeine group compared to the placebo group,
36·4&10·2 mg vs. 95·1&24·6 mg, respectively. However,
there was no significant diVerence in the number of patients
willing to repeat the procedure between the two groups
(Table 2).
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We consider that the most important factor for safe bron-
choscopic examination is complete local anaesthesia of the
airway. Hatton et al. (2) suggested that sedation was not
significantly more eVective than a placebo regarding patient
comfort or their willingness to undergo a repeat procedure.
They concluded that routine sedation is of little use for
patients undergoing single diagnostic fibre-optic bron-
choscopy. However, our results showed that sedation is
essential even in single diagnostic procedures. In particu-
lar, patients who demonstrate a strong pharyngoreflex,
nervousness (including children), or a past history of pain-
ful bronchoscopy are considered to require sedation. Some
of our patients with strong pharyngoreflexes could not
continuously inhale local anaesthetic drugs such as xylo-
caine spray due to severe cough. These patients noted
pain during the procedure because the local anaesthesia
was incomplete. Therefore, we consider sedation to be
important.
Midazolam is well established and widely used as a
sedative agent in patients undergoing fibre-optic examin-
ation. Midazolam produces amnesia and anxiolytic
eVects, so patients undergoing bronchoscopy do not feel
pain during the procedure. Doses of i.v. midazolam
(0·07 mg kg"1) suggested for sedation may not produce
complete amnesia as reported, as mentioned above (2).
William et al. (3) suggested that higher doses, mean
0·24 mg kg"1, of midazolam produce complete amnesia
without serious problems. In this study, we used
0·15 mg kg"1. This dose produced suYcient amnesia, as no
patient remembered any situation during bronchoscopy.
Based on our experience, incomplete local anaesthesia
induces severe cough and physical movement during bron-
choscopy even under midazolam sedation. Therefore, bron-
choscopy is diYcult unless supplemental local anaesthesia is
employed. Midazolam is a useful sedative agent but does
not exhibit anti-tussive eVects (4). Therefore, we used
codeine phosphate as a premedication to repress induced
cough and physical movement.
In our study, the dose of supplemental local anaesthesia
required was significantly lower in the codeine group than
in the placebo group. Codeine phosphate was eVective to
repress induced cough during the procedure. The functional
expression time of this drug is 30 min after oral medication,
and the drug is eVective for more than 90 min. Therefore,
the patients received codeine phosphate 60 min prior to
bronchoscopy.
Oxygen desaturation was noted when the patients exhib-
ited productive coughing. The number of patients whose
lowest saturation was under 90% was significantly higher in
the placebo group compared to the codeine group. Thecodeine group showed a significantly higher value of the
mean lowest oxygen. This result indicates that the anti-
tussive eVect of codeine phosphate was eVective during
bronchoscopy. However, there was no significant diVerence
in the number of patients willing to undergo the same
examination if necessary. No patient remembered coughing
during bronchoscopy because midazolam causes amnesia.
The findings showed that bronchoscopy can be performed
more easily and safely using codeine phosphate.
It has been reported that sedation for bronchoscopy is
associated with major complications (5,6). Severe side-
eVects of midazolam include depression of the root of the
tongue, apnoeic pause, hypopnoea and anaphylactic shock.
Only one case exhibited apnoeic pause and the patient was
not hypoxycemic or hypercapnic. However, tracheal aus-
cultatory sound was suspected to be stenotic due to tracheal
invasiveness of thyroid cancer recurrence. Sedation is con-
traindicated for patients with forced respiration due to
central airway obstruction despite good results of arterial
blood gas analysis. Monitoring the ECG, pulse oximetry
and blood pressure during bronchoscopy are essential,
and we strongly recommend breathing bag or tracheal
intubation preparation for unexpected respiratory pause.
Moreover, we prepare fluamzenil in a syringe for urgent
reversal of sedation before administering midazolam.
We conclude that codeine phosphate is eVective in
repressing induced coughing during bronchoscopy.
Midazolam is a useful sedative agent to produce amnesia
in patients who exhibit incomplete local anaesthesia. Pre-
medication codeine phosphate is beneficial for both the
patient and bronchoscopist.References
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